Oligonucleotide Preclinical Licensing Benchmarks
Deal economics across 16 transactions with 12 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$78M
12 deals with terms
Median Total Value
$1.3B
Upfront + milestones
Deal Count
16
2022--2026
The median upfront payment for preclinical oligonucleotide licensing deals is $78M, based on 12 deals with disclosed terms from 2022--2026. Total deal values (including milestones) reach a median of $1.3B. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Siran Biotechnology | GSK | 2026 | $1.0B | $1.0B |
| Arrowhead | Sarepta | 2024 | $500M | -- |
| Alnylam | Regeneron | 2023 | $200M | -- |
Showing 3 of 12 deals with disclosed terms. Full comp set available in the report.
Full Oligonucleotide Preclinical Comp Set
Get the complete analysis -- 12 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific oligonucleotide asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2022--2026). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.